Tue Sep 24 04:20:54 UTC 2024: ## StageZero Life Sciences Stock Soars 88.5% on Monday
**OTCMKTS:GNWSF** shares surged a staggering 88.5% on Monday, closing at $0.15 after reaching a high of $0.70. The significant increase in share price came on unusually low trading volume, with only 2,783 shares changing hands, a 90% drop from the average daily volume.
StageZero Life Sciences, a company focused on developing and commercializing molecular diagnostic tests for early disease detection and personalized health management, particularly in cancer-related indications, has seen its stock perform strongly in recent weeks. The company’s proprietary Sentinel Principle technology, which identifies novel biomarkers from whole blood, is a key driver for its growth.
Despite the strong performance, the company remains relatively small with a market cap of $9.50 million. Investors should note that StageZero Life Sciences is a speculative investment with a negative PE ratio of -0.54.
**Disclaimer:** This news article is for informational purposes only and should not be considered investment advice. Always consult with a qualified financial professional before making any investment decisions.
First Piper 